Cubist Systematic Strategies’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Cubist Systematic Strategies’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,700	Closed	-$1.19M	–	4180
2023 Q2	$1.19M	Buy	+11,700	New	+$1.11M	0.01%	1852

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Cubist Systematic Strategies's RETA Position: Q2 2023 in Review

Cubist Systematic Strategies sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 34,946 shares — an estimated $3.31M sold.

Cubist Systematic Strategies first reported a position in RETA in Q2 2018 and held it in 20 quarters. The position peaked at $3.52M in Q1 2021. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Cubist Systematic Strategies reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Cubist Systematic Strategies sold 34,946 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $3.31M.
Cubist Systematic Strategies first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2018 and held it in 20 quarters.
Cubist Systematic Strategies's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3.52M in Q1 2021.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Cubist Systematic Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.